Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) (Style)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03449173
Recruitment Status : Recruiting
First Posted : February 28, 2018
Last Update Posted : March 27, 2018
Sponsor:
Information provided by (Responsible Party):
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Brief Summary:
Study to investigate response to sunitinib in patients with thymic epithelial tumours who had progressive disease after at least one previous regimen of platinum-based chemotherapy.

Condition or disease Intervention/treatment Phase
Type B3 Thymoma Thymic Carcinoma Drug: Sunitinib Phase 2

Detailed Description:

This trial will be conducted to assess the activity of Sunitinib in patients affected by advanced or recurrent B3 thymoma or thymic carcinoma progressing after at least one line of chemotherapy (including one platinum based regimen).

Taking into account the different biology and historically discrepant responses and survival of thymoma and thymic carcinoma, patients will be enrolled with these tumour types in two separate cohorts.

Sunitinib will be self orally administered at 50 mg once daily, is 50 mg taken orally once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks until tumour progression, unacceptable toxicity or other criteria for discontinuation is met.

Sunitinib dose reductions are permitted as per the approved product label for safety reasons.

Dose reductions should occur in 12.5 mg decrements. No more than 2 dose reductions are allowed. If more than 2 dose reductions are necessary (ie, reduction to less than 25 mg daily), the subject must be permanently discontinued (Section 7.2.2)

Possible dose reductions:

  • Sunitinib at dose of 37,5 mg orally once daily for 4 weeks followed by 2 weeks rest-period in cycles of 6 weeks.
  • Sunitinib at dose of 25 mg orally once daily for 4 weeks followed by 2 weeks rest-period in cycles of 6 weeks

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)
Actual Study Start Date : March 2, 2017
Estimated Primary Completion Date : March 2, 2021
Estimated Study Completion Date : March 2, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thymus Cancer

Arm Intervention/treatment
Experimental: Sunitinib
Sunitinib orally administered at 50 mg once daily for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks
Drug: Sunitinib
small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor
Other Name: Sutent




Primary Outcome Measures :
  1. Activity of Sunitinib [ Time Frame: 4 years ]
    Best tumour response (Complete Response + Partial Response)


Secondary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: 4 years ]
    The PFS is defined as the time from the date of randomization to the date of documented progressive disease, recurrence or Death (whichever occurs first)

  2. Overall Survival (OS) [ Time Frame: 4 years ]
    The OS is defined as the time from the date of randomization to the date of death

  3. Duration of activity of sunitinib [ Time Frame: 4 years ]
    Complete Response + Partial Response + Stable Disease

  4. Safety and toxicity profile of sunitinib [ Time Frame: 4 years ]
    will be utilized the CTCAE v 4.0 criteria for assessment of toxicity and serious adverse event reporting.

  5. Incidence of adverse events (AEs) [ Time Frame: 4 years ]
    Incidence of adverse events (AEs) will be graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.0, laboratory values, physical examinations, vital signs.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed and dated IRB (Independent Review Board)/IEC (Independent Ethics Committee)-approved Informed Consent
  2. Histological diagnosis of invasive recurrent or metastatic type B3 thymoma or thymic carcinoma. In case of presence of both histologies it will be classified based on the predominantly part. B2 thymoma with areas of B3 thymoma are eligible.
  3. Patients must have had at least one prior platinum-containing chemotherapy regimen. There is no limit to the number of prior chemotherapy regimens or targeted agents received. Progressive disease should have been documented before entry into the study
  4. Patients must have measurable disease, defined as at least one lesion that can be accurately measured according with RECIST 1.1 criteria
  5. Availability of archival tissue (paraffine block or at least 10 unstained slides)
  6. Patients must have recovered from toxicity related to prior therapy to at least grade 1 (defined by v.CTCAE 4.0)
  7. Patients must not have had major surgery, radiation therapy, chemotherapy, biologic therapy (including any investigational agents), or hormonal therapy (other than replacement), within 4 weeks prior to entering the study
  8. Age > 18 years
  9. Life expectancy > 3 months
  10. Performance status (ECOG) ≤ 2
  11. Negative pregnancy test (if female in reproductive years)
  12. Patients must have adequate organ and marrow function (as defined below). Patients must have returned to baseline or grade 1 from any acute toxicity related to prior therapy:

    • Absolute neutrophil count ≥ 1,500/mm
    • Hemoglobin ≥ 9 g/dL
    • Platelets ≥ 100,000/mm
    • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) , except for patients affected by Gilbert's syndrome
    • AST(SGOT) (aspartate aminotransferase) /ALT(SGPT) (alanine transaminase) ≤ 3 x institutional ULN (5x if LFT (liver function test) elevations due to liver metastases)
    • Creatinine ≤ 1.5 x institutional ULN
  13. Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception before study entry, for all the duration of the study and for at least 8 weeks after the last dose of investigational drug (30 days for an ovarian cycle turnover plus the time required for the active metabolite of sunitinib to undergo five half-lives).
  14. Males who are sexually active with WOCBP must agree to follow instructions for method(s) of before study entry, for all the duration of the study and for at least 16 weeks after the last dose of investigational drug (90 days for sperm turnover plus the time required for the active metabolite of sunitinib to undergo five half-lives).

Exclusion Criteria:

  1. untreated CNS metastases. Patients with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) ending at least 2 weeks prior to start of treatment, or after surgical resection performed at least 28 days prior to start of treatment. The patient may have no evidence of Grade ≥1 CNS haemorrhage based on pre-treatment Magnetic Resonance Imaging (MRI) or IV contrast CT scan (performed within 28 days before start of treatment)
  2. Major surgery, other than diagnostic surgery, within 4 weeks prior to treatment
  3. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  4. Pregnant or breast feeding women
  5. Previous (within the last 5 years) or current malignancies at other sites, except for adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri
  6. Current enrollment in or participation in another therapeutic clinical trial within 4 weeks before treatment start.
  7. Patients with uncontrolled or significant cardiovascular disease (AMI within 12 months, unstable angina within 6 months, NYHA (New York Heart Association) Class III, IV Congestive heart failure or left ventricular ejection fraction below local institutional lower limit of normal or below 45%,
  8. Ongoing symptomatic cardiac dysrhythmias, uncontrolled atrial fibrillation, or prolongation of the Fridericia corrected QT (QTcF) interval defined as > 450 msec for males and > 470 msec for females, where QTcF = QT / 3√RR
  9. Poorly controlled hypertension
  10. History of cerebrovascular accident including transient ischemic attack within the past 12 months.
  11. History of deep vein thrombosis (DVT) unless adequately treated with low molecular weight heparin
  12. History of pulmonary embolism within the past 6 months unless stable, asymptomatic, and treated with low molecular weight heparin for at least 6 weeks.
  13. Evidence of active bleeding or bleeding susceptibility; or medically significant hemorrhage within prior 30 days.
  14. Receiving concomitant CYP3A4 inducers or strong CYP3A4 inhibitors
  15. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of sunitinib
  16. Known HIV infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03449173


Contacts
Layout table for location contacts
Contact: Marina Chiara Garassino, MD +390223903813 marina.garassino@istitutotumori.mi.it
Contact: Rosaria Gallucci, MSc +390223903836 rosaria.gallucci@istitutotumori.mi.it

Locations
Layout table for location information
Italy
National Cancer Institute Recruiting
Milan, Italy, 20133
Sponsors and Collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Investigators
Layout table for investigator information
Principal Investigator: Marina Chiara Garassino, MD National Cancer Institute (NCI)

Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
ClinicalTrials.gov Identifier: NCT03449173     History of Changes
Other Study ID Numbers: INT 165-16
First Posted: February 28, 2018    Key Record Dates
Last Update Posted: March 27, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Thymoma
Thymus Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Complex and Mixed
Thoracic Neoplasms
Neoplasms by Site
Lymphatic Diseases
Sunitinib
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action